Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

BACKGROUND: In the AVAGAST study, fluoropyrimidine and cisplatin plus bevacizumab did not significantly improve overall survival (OS) versus fluoropyrimidine and cisplatin plus placebo in patients with advanced gastric cancer. Geographic differences in efficacy were observed in AVAGAST, but the stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Lin, Li, Jin, Xu, Jianming, Pan, Hongming, Dai, Guanghai, Qin, Shukui, Wang, Liwei, Wang, Jinwan, Yang, Zhenzhou, Shu, Yongqian, Xu, Ruihua, Chen, Lei, Liu, Yunpeng, Yu, Shiying, Bu, Lilian, Piao, Yongzhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544634/
https://www.ncbi.nlm.nih.gov/pubmed/24557418
http://dx.doi.org/10.1007/s10120-014-0351-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544634/
https://www.ncbi.nlm.nih.gov/pubmed/24557418
http://dx.doi.org/10.1007/s10120-014-0351-5

Ejemplares similares